Læknablaðið - 01.06.1965, Qupperneq 18

LÆKNABLAÐIÐ
When hypertensive
complications threaten
Nefrolan
enables the physician to
improve the patient's
prognosis.
A product of
May & Baker Research
Whether symptomless or not, hypertension can
be effectively treated with 'Nefrolan'* brand of
clorexolone without fear of inducing distressing
side-effects. Thus, by reducing high blood pressure
to a safe level, the development of its serious and
often irreversible complications is prevented.
Where a more profound anti-hypertensive effect is
required, 'Nefrolan' may be given in conjunctlon
with reduced doses of more potent hypotensive
agents. This minimises any resultant side-effects
of the more potent drug.
As with all anti-hypertensive agenls, however, the
administration of 'Nefrolan' shouid not be initiated
prior to a full clinical investigation,
At high dosage levels, ‘Nefrolan' is also an
effective oral diuretic.
Available as tablets of
10 mg. for hypotensive use
25 mg. for diuresis and more severe hypertension.
Dagenham Essex England
HA lí!l R
Ágants in tceland: Stefan Thorarensan Ltd., P.O. Box 897, Reykjavik Tel: 81616/8